ELDN Stock Analysis: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$2.70
-0.13 (-4.59%)
▼
5d:
-12.9%
30d:
+3.05%
90d:
+68.75%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
ELDN is down 5.5% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 2,679 OI. Call ratio: 100% View Scanner →
Strength: 7.8/10
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ELDN is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ELDN is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $2.70, which is considered slightly high relative to its 30-day fair value range of $2.38 to $2.93.
Technical Outlook: Technically, ELDN is in a uptrend. The price is currently testing key support at $2.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+182.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELDN is in a uptrend. The price is currently testing key support at $2.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+182.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$2.38 -
$2.93
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 182.7% below Wall St target ($8.00)
- WARNING: Recommendation downgraded due to -12.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.38 -
$2.93
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.72
Resistance Level
$3.19
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.52
Wall Street Target
$8.00
(+182.7%)
Share & Embed Analysis
Last updated: March 30, 2026 2:53 PM ET
Data refreshes hourly during market hours. Next update: 3:53 PM
Data refreshes hourly during market hours. Next update: 3:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 54 HOLD |
